Skip to main content

Table 7 Cox regression on retention for monotherapy versus aggregated combination therapies

From: A pilot trial of quetiapine, lithium, or placebo added to divalproex sodium for hypomanic or manic episodes in ambulatory adults with bipolar I disorder

Variable B SE Wald P Hazard ratio 95% CI
Group
 Monotherapy
 Combination therapy 0.93 (0.92) 0.48 (0.48) 1.94 (1.90) 0.052 (0.058) 2.56 (2.51) 0.99–6.61 (0.97–6.50)
Side effect severity 0.02 (0.02) 0.08 (0.09) 0.27 (0.27) 0.785 (0.785) 1.02 (1.02) 0.87–1.21 (0.86–1.21)
Side effect severity × group 0.01 (0.00) 0.09 (0.09) − 0.43 (0.01) 0.939 (0.992) 1.01 (1.00) 0.85–1.20 (0.84–1.19)
YMRS 0.00 (− 0.00) 0.03 (0.03) 0.04 (− 0.03) 0.965 (0.973) 1.00 (1.00) 0.95–1.06 (0.95–1.05)
HAM-D 0.06 (0.07) 0.03 (0.03) 1.74 (2.06) 0.082 (0.039*) 1.06 (1.07) 0.99–1.14 (1.00–1.14)
Site − 1.02 1.05 − 0.97 0.334 0.36 0.05–2.85
  1. Estimates for the model that excluded site are shown in parentheses
  2. Monotherapy: divalproex plus placebo; combination: combination therapy of divalproex plus blinded lithium and divalproex plus blinded quetiapine
  3. Monotherapy (“–”) was used as the reference group
  4. *Significant at p < 0.05